- Home
- RGLS
RGLS
Regulus Therapeutics Inc.
as 06-20-2025 4:00pm EST
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | N/A | IPO Year: | 2012 |
| Target Price: | $8.50 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.83 - $8.35 | Next Earning Date: | 08-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Regulus Therapeutics Inc. (RGLS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Klassen Preston | RGLS | President & Head of R & D | Jun 3 '25 | Buy | $7.99 | 12,000 | $95,852.40 | 48,055 |
Latest Regulus Therapeutics Inc. News
RGLS Breaking Stock News: Dive into RGLS Ticker-Specific Updates for Smart Investing
Associated Press Finance
a month ago
Regulus: Q1 Earnings Snapshot
PR Newswire
a month ago
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates
LA Times
2 months ago
Novartis to buy Regulus Therapeutics for as much as $1.7 billion
TipRanks
2 months ago
Biotech Alert: Searches spiking for these stocks today
MT Newswires
2 months ago
Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6
MT Newswires
2 months ago
Oppenheimer Downgrades Regulus Therapeutics to Market Perform From Outperform
Pharmaceutical Technology
2 months ago
Novartis to strengthen renal disease portfolio with Regulus
MT Newswires
2 months ago
Sector Update: Health Care Stocks Rise Wednesday Afternoon
Compare RGLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RGLS Regulus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.